🇺🇸 FDA
Patent

US 11617801

RP2 and RPGR vectors for treating X-linked retinitis pigmentosa

granted A61KA61K38/1709A61K48/005

Quick answer

US patent 11617801 (RP2 and RPGR vectors for treating X-linked retinitis pigmentosa) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/1709, A61K48/005, A61K48/0058, A61P